

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
7 August 2003 (07.08.2003)

PCT

(10) International Publication Number  
WO 03/065033 A2

(51) International Patent Classification: G01N 33/48

Stephen; 525 Clara Avenue #202, St. Louis, MO 63112 (US).

(21) International Application Number: PCT/US03/02429

(74) Agent: DIGIROLAMO, Samuel; Blackwell Sanders Pepper Martin LLP, 720 Olive Street, Suite 2400, St. Louis, MO 63101 (US).

(22) International Filing Date: 27 January 2003 (27.01.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
10/059,084 28 January 2002 (28.01.2002) US(71) Applicant: CONTROL DIABETES, INC. [US/US];  
6520 Clayton Road, St. Louis, MO 63117 (US).


(72) Inventors: BORTZ, Jonathan, David; 8117 Stanford Avenue, St. Louis, MO 63130 (US). ARMBRECHT, Eric,

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, IIR, IU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: METHODS AND SYSTEMS FOR ASSESSING GLYCEMIC CONTROL USING PREDETERMINED PATTERN LABEL ANALYSIS OF BLOOD GLUCOSE READINGS



(57) Abstract: Methods and systems for analyzing blood glucose readings comprising the steps of obtaining a plurality of blood glucose readings taken within a predetermined time category and time period, performing first calculations on said readings based on a predetermined normal range of glycemia in a first analysis and selecting and applying a pattern label having predetermined criteria to the plurality of blood glucose readings by comparing the results of the first calculations to the pattern label criteria. The invention may also include the steps of performing second calculations on said readings based on predetermined thresholds for severe hyperglycemia and severe hypoglycemia and selecting and appending a severity suffix having predetermined severity criteria to said pattern label by comparing the results of the second calculations to the severity criteria as well as performing third calculations on said readings based on a predetermined normal range of glycemia and selecting and appending a minor comment having minor comment criteria to said pattern label by comparing the results of the third calculations to the comment criteria.

WO 03/065033 A2



European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

*without international search report and to be republished  
upon receipt of that report*

**METHODS AND SYSTEMS FOR ASSESSING GLYCEMIC CONTROL**  
**USING PREDETERMINED PATTERN LABEL ANALYSIS OF BLOOD**  
**GLUCOSE READINGS**

Field of the Invention

The present invention is in the field of chemical arts, specifically, the field of blood glucose level analysis.

5 Background of Invention

Proper analysis of blood glucose levels is crucial to providing optimal care to diabetic patients. However, proper analysis of blood glucose levels for even a single patient requires the analysis of mountains of individual readings from various time categories taken over various spans to determine the clinical significance of the individual readings and any information shown by groups of readings. Such analysis is time-consuming and tedious for medical professionals to perform on any significant scale.

Moreover, the lack of generally accepted analytical terms for analyzing the raw blood glucose reading data increases the complexity of the analysis' and burdens the exchange of analysis data between medical professionals. This makes it more difficult for medical professionals to correlate a given series of readings with the proper course of medical intervention. Of course, it also makes educating patients about their own condition and treatment options difficult.

### Summary of Invention

The invention is a method and computer system for analyzing blood glucose readings comprising the steps of obtaining a plurality of blood glucose readings taken  
5 within a predetermined time category and time period, performing calculations on said readings and selecting and applying a pattern label having predetermined criteria to the plurality of blood glucose readings by comparing the results of the calculations to the pattern label criteria.

Such embodiment may also include the steps of performing second  
10 calculations on said readings based on predetermined thresholds for severe hyperglycemia and severe hypoglycemia and comparing the results of said second calculations to predetermined severity criteria and selecting and appending a severity suffix to said pattern label or determining that no severity suffix is necessary. The invention may also include performing third calculations on said readings based on a  
15 predetermined normal range of glycemia and comparing the results of the third calculations to predetermined minor comment criteria to select and append a minor comment to said pattern label based.

In light of the foregoing and the following description of the invention, it is one object of the present invention to provide a method for analyzing a plurality of  
20 blood glucose readings by assigning pattern labels -- clinically significant but previously undefined terms which identify clinically actionable distributions of blood glucose measurements -- to categories of the readings and outputting a glucose control assessment based thereon.

It is another object of the invention to provide automated, computer implemented systems for the implementation of the inventive method.

Other objects and advantages of the present invention are identified in the drawings, specification and claims herein or will otherwise be apparent to those skilled in the art. While the invention has been disclosed herein in various embodiments and examples, it is subject to various modifications and alternative forms. Nothing in this specification is intended to or may be interpreted to limit the scope of the invention as determined by the broadest possible interpretation of the appended claims.

10

#### Brief Description of Drawings

Figure 1 is a flow chart of one embodiment of the present inventive method and system;

Figure 2 shows the default pattern labels and pattern label criteria;

15

Figure 3 shows the default severity suffixes and severity suffix criteria;

Figure 4 shows the default minor comments and minor comment criteria;

Figure 5 is an example of one possible output of the inventive system showing a sample assessment of glycemic control for a hypothetical patient with pattern labels for various time categories;

Figure 6 is another exemplar output of the inventive system showing a sample assessment and report of glycemic control for a hypothetical patient with pattern labels for various time categories;

Figure 7 is an output report of the system showing sample raw blood glucose reading data and patient provided comments; and

Figure 8 shows calculation results used in one embodiment of the invention.

#### Detailed Description

The methods and systems of the present invention classify infinite possibilities of blood glucose readings into a finite number of clinically meaningful statements about a patient's glycemic control. As such, the invention assists medical professionals to efficiently and consistently assess a patient's glycemic control and administer proper clinical intervention as necessary.

A preferred embodiment of the invention comprises a computer system implementing the inventive method for automatically analyzing blood glucose readings in a given time category and time period comprising the steps of obtaining a plurality of blood glucose readings taken within a predetermined time category and time period, performing calculations on said readings based on a predetermined normal range of glycemia and selecting a pattern label having predetermined criteria by comparing said criteria to said calculation results to assess a human patient's glycemic control.

The present invention also provides for severity checks and commentary, called severity suffixes, based on analysis of the plurality of readings in the time category. In this way, both the overall pattern of the readings and discrete severe readings are analyzed and reported on by the method and system. In addition, the  
5 invention may provide a minor comment, for example, where severity suffixes are not necessary, to further explain the readings. Thus, the full pattern label of the present invention may comprise the base pattern label, a severity suffix (if selected), and/or a minor comment.

The blood glucose patterns of the present invention comprise clinically  
10 significant terms which identify clinically actionable distributions of blood glucose measurements but which do not presently have generally accepted definitions within the art of glucose reading analysis. The default and preferred set of standardized pattern labels and label criteria of the invention are shown in Figure 2.

By analyzing the glucose reading data via patterns rather than statistical  
15 calculations of the data (e.g., standard deviations, means, skewness, etc.), the method achieves clinical significance in a manner that can be understood by the lay healthcare provider. Patterns, as opposed to statistical calculations, represent a more natural analysis of glucose readings when blood glucose readings are used for treatment decisions by health care providers.

20 The analysis procedure is conducted by a computer system that obtains daily blood glucose readings and other data necessary for treatment decisions through multiple channels. Blood glucose reading data may be submitted to a database by manual data entry, over the Internet, by telephone or on a paper form. In addition,

data may be obtained directly from the diagnostic device that analyzed the blood to yield the reading. Depending on the preferences of the user, an output report may be displayed on a computer screen, or communicated via fax, email or postal mail. Such a report may display the raw data, graphical representations of the data and a  
5 glycemic control report as determined by the invention.

Figure 1 shows the general process 100 of one embodiment of the present invention culminating in assessing glycemic control 124. A glycemic control report is constructed by analyzing the data for each time category separately. Examples of such a report are shown in Figures 5 and 6 as references 500 and 602.

10 The first step in the method involves obtaining a plurality of blood glucose readings 101. Either before or after the blood glucose readings are made, a user selects 102 desired settings preferably via computer software driven menus. Such setting may include selecting the analysis time period, the time category under investigation 106, the data weighting desired and the normoglycemia range.

15 The analysis time period is the date range over which blood glucose readings to be analyzed are taken. A Begin Date and End Date may be set to cover any time period. The default time period may be 30 days and may be adjusted by the user as necessary.

Time categories are recognized as intra-day periods in which blood glucose  
20 readings are taken. The present invention accommodates at least the following standardized and preferred time categories:



- |                    |                   |
|--------------------|-------------------|
| • Before Breakfast | • After Breakfast |
| • Before Lunch     | • After Lunch     |
| • Before Dinner    | • After Dinner    |
| • Before Bedtime   | • Nighttime       |

- 5 Although such standardized categories are specified in the system by default, they may be modified or amended as necessary by the user.

- The system or a data collection instrument (e.g., web-enabled software application, paper-based logbook, glucometer, etc.) manages or at least facilitates the system's allocation of glucose reading data to one of the time categories. When
- 10 multiple time categories are to be analyzed, each is analyzed independently and the resulting pattern labels combined in the assessing glycemic control step 124 for the time period.

- Data weighting is a method by which some readings, for example, more recent blood glucose readings, are given greater influence in the analysis. This may be
- 15 accomplished by multiplying each reading over a specified period of time (e.g., the most recent 10 days) by a positive integer, thereby changing the influence of the glucose readings during that period in the overall analysis. For example, if a data set contains 30 blood glucose readings (one on each day at the same time category of the specified analysis period) and 10 glucose readings from the most recent 10 days of the
- 20 analysis period are given a weight of 2, then each of the glucose readings during that specified period would count twice as much as the others in the data set. The weighting convention is made available to account for the relative importance of recent glucose readings over older glucose readings.

In defining settings 102, the user may also define the blood glucose range which represents the normal range of glycemia or normoglycemia. The default and preferred standardized normal range is 71-150 mg/dl for all time categories except Before Breakfast. The default Before Breakfast normal range is 71-125 mg/dl. The  
5 normal range may be modified by the medical professional for each patient, each time period and at each time category, but once set, is the same for all analysis done within each time category.

Once the settings 102 are established and the blood glucose readings are obtained, the blood glucose readings are loaded 104 into the computer system. This  
10 may be accomplished in many ways known in the art, including via the Internet, modem transfer, scanner/digitizer, upload from a glucometer or even direct data entry. Then, if not already established in the settings 102 step, the user may select the appropriate time category 106 at issue in order to filter the relevant readings for analysis.

15 As the invention uses customizable pattern labels having customizable criteria, alternative sets of labels and corresponding criteria may be selected prior to analysis 110, for example, at the defined settings 102 step. Shown in Figure 2 is a representation of the default pattern label set 200 used for the inventive analysis. The default set of labels and criteria, shown in Figure 2, are preferred and provide the  
20 highest level of standardization of analysis. However, the labels 201 and their attendant criteria 202 may be customized by the medical professional within the limit of the need to create mutually exclusive criteria and labels. Customization of the pattern label set 200 may occur at the patient-level or at a system level that would be

applicable to all patients. The customized labels 201 and/or criteria 202 may be maintained by the system in sets akin to the default set 200 which are selectable by the user.

For example, "Optimal Control" could be defined differently for an obese,  
5 Type 2 diabetic versus a 23-year old woman with gestational diabetes. Therefore, a system administrator may modify the "Optimal Control" label criteria to make the former patient's control requirements more stringent, thereby creating a custom label set for that patient or type of patient. Thus, the present invention affords healthcare providers the flexibility to define their own terms for analysis to ensure proper care.

10 In the next step, various calculations 108 are performed on the readings to provide for the selection of the pattern label. A preferred embodiment of the calculations is illustrated, with exemplar results, in Figure 8. The calculations may include counting the number of readings in the time category for the time period; computing the percentages of readings above, below and within the normal range of  
15 glycemia; and computing the means of readings above, below and within the normoglycemia range. For the severity suffix analysis 112, they may include counting the number of blood glucose readings above and below predetermined high and low threshold values of glycemia. High and low thresholds may be based on the numerical distance from the upper and lower bounds of the normal range of glycemia.  
20 Other thresholds used in the calculations, for example, those for the minor comments as shown in Figure 4, may also be based on the upper and lower bounds of the normal range of glycemia.

To ensure relevancy of the calculation, a minimum number of readings must occur in the defined time period in order for the assessing 124 to take place. The preferred number of readings necessary to support application of the various pattern labels 201 for a reasonable analysis of the readings are shown in Figure 2 under the

5 heading "Minimum No. of Readings."

The percentage of readings that fall within the default preferred standardized normal range of glycemia (e.g., 71-150 mg/dl) may be calculated by dividing the number of readings that occur within normal range by the total number of readings in the time category and multiplying that number by 100. The percentage of readings

10 that fall below normal range may also be calculated for the time category by dividing the number of readings that occur below normal by the total number of readings multiplied by 100. The percentage of readings that fall above the normal range may be calculated for the time category by dividing the number of readings that occur above normal by the total number of readings multiplied by 100.

15 The mean of readings that fall within the normal range may be calculated for the time category by summing the values of all the normal range readings and dividing by the total number of normal range readings. The mean of readings that fall below (e.g., <71 mg/dl) the normal range may be calculated for the time category by summing the values of all the below normal range readings and dividing by the total

20 number of below normal range readings. The mean of readings that fall above (e.g., >150 mg/dl) the defined normal range may be calculated for the time category by summing the values of all the above minimal range readings and dividing by the total number of above range readings. In this way, the lay user comprehension of the

pattern of blood glucose readings may be enhanced as the analysis is expressed as percentages rather than complicated statistics such as standard deviations and other measures of variance, correlation or central tendency.

To select a pattern label, the calculation results may be compared to the pattern label criteria 202 for the selected label set, in a step-wise manner. A patient's glucose readings for each time category may be filtered through the criteria using the following logic:

"if the calculations on a patient's collected glucose readings match the predetermined criteria for pattern label x, then report pattern label x."

For example, the calculation results are compared to the criteria for the Excellent Control label. If all the criteria fit the results, the label is selected and attached to the data set. If not, the criteria are compared to the Optimal Control label and so on through the pattern label set 200 until the calculation results match a single pattern label criteria.

While a step-wise selection system is used in the preferred embodiment, it is understood that other known methods of data-analysis may also be suitable. For example, rather than comparing the results to the criteria for an individual label, the system may compare the results to an entire class of criteria (i.e., Minimum No. of Readings, Below Normal Percentage, etc.) across the various pattern labels at a time. Thus, the system would filter out the single appropriate pattern as each class of criteria filters out the inappropriate labels.

Severity Suffix

The system and method may also include second calculations for a Severity Analysis 112 for extreme blood glucose readings. The default set 301 of Severity Suffixes 300 and their criteria 302 are shown in Figure 3. The preferred second  
5 calculations for the Severity Analysis 112 are shown in Figure 8. Such analysis may comprise conducting second calculations and comparing the results of those second calculations to the Severe Suffix criteria 302 to identify and select a severity suffix (generally 300, with specific examples shown as 506 and 508 in Figure 5) to append  
10 to the pattern label. The number of blood glucose readings that occur below the severe hypoglycemia threshold may also be counted for the time category. The default severe hypoglycemia threshold is 40 mg/dl. Also, the number of blood glucose readings that occur above the severe hyperglycemia threshold may be counted for the time category. The default severe hyperglycemia threshold is 400 mg/dl.

As with the pattern label analysis 110, the severity analysis 112 may comprise  
15 a step-wise comparison of the severity suffix criteria 302 and a pattern label severity suffix 300 is added to the pattern label in the presence of severely hyperglycemic or hypoglycemic readings. In the absence of such readings, i.e., where the severity suffix criteria 302 are not met 116, no suffix may be added and a minor comment analysis 114 may be conducted.

Minor comment

20 The invention may also conduct a minor comment analysis 114 based on the blood glucose readings to paint a more complete picture of the patient's glycemic control when no severity suffix is appropriate 116. Table 4 identifies the various

default minor comments 400 and the criteria 402 used by the system to append them to the pattern label using the step-wise procedure previously discussed. In general, the minor comments 400 provide greater detail to the analysis provided by the pattern label itself. This additional modifying clause to the pattern label gives the healthcare provider additional information that might otherwise be overlooked.

Third calculations, those for the minor comment analysis, may comprise calculating the mean of readings below a normal range of glycemia ("below normal mean" in Figure 4), the mean of readings within a normal range of glycemia ("within normal mean"), and the mean of readings above a normal range of glycemia ("above normal mean"). Other third calculations may include computing the thresholds used in the minor comment criteria. For example, the criteria for the "with notable hypoglycemia" minor comment for the pattern label "Optimal Control," utilizes a threshold of 0.8 multiplied by the lower bound of the predetermined normal range of glycemia. Thus, a data set having an Optimal Control pattern label with a "below normal mean" of less than that threshold, would result in the selection of the "with notable hypoglycemia" minor comment. Of course, many, if not all, of the minor comment calculations may be done when the calculations for the pattern label and/or severity suffix are made.

As with the pattern label itself, the severity suffix and minor comment, as well as their respective criteria, are customizable within the limit of having each label and its respective criteria mutually exclusive of the others.

Once the pattern label 110, severity suffix 112 and minor comment analyses 114, if any, are complete, the complete pattern label 510 for the time category is assembled in the time category summary step 118.

The method described above is repeated 120, 122 for all other time categories  
5 until all desired time categories have been analyzed whereupon the analysis proceeds to assessing glycemic control 124, which may comprise compiling the pattern labels for all the time categories analyzed and creating at least one glycemic control report 500 for the period analyzed as shown in Figure 5.

In this way, raw blood glucose readings, such as those shown in report format  
10 in Figure 7, are converted from raw data to an easy-to-read, clinically meaningful glycemic control report 500, to assist the medical professionals in diabetes treatment and the patients in educating themselves as to their conditions. Examples of such reports are shown as reference numerals 500 and 602 in Figures 5 and 6, respectively. Figure 6 also illustrates a glycemic control report 602 as part of a larger data report  
15 presenting other glycemic control data. Figure 7 shows the specific raw data 702 used to provide the report 602.

### **Example**


To further explain a preferred embodiment of the present invention, the following example is presented with the calculation results discussed herein charted in  
20 Figure 8. Jane Doe, a hypothetical patient, is a middle-aged Type I diabetic who tests her blood four times during the day: before breakfast, before lunch, before dinner, and before bedtime. Of the 30 days between January 1 and January 30, she tested and records her blood glucose levels 22 times before dinner (data shown as columns 702



in Figure 7). She uploaded her data into the inventive system via her glucometer, her home computer, and an Internet connection. Her physician has elected to use the default, preferred pattern label sets, normoglycemia range, severity suffix set and minor comment label and criteria. For purposes of example, the analysis of data from

5 the before dinner time category is discussed herein.

Jane Doe's before dinner blood glucose readings are:



The system calculations are made as follows: six of the 22 readings are between 71-150 mg/dl. Thus, 27.3% of Before Dinner readings from January 1 to

10 January 30 are normal.

In the Jane Doe example, 2 of the 22 readings in Figure 1 are below 71 mg/dl. Thus, 9.9% of Before Dinner readings from January 1 to January 30 are below normal.

In the Jane Doe example, 14 of the 22 readings in Figure 1 are above 150 mg/dl. Thus, 63.6% of Before Dinner readings from January 1 to January 30 are above normal.

In the Jane Doe example, the within-normal range mean equals 131.6 mg/dl  
5 calculated as follows:

$\Sigma(110, 122, 133, 136, 141, 148)=790$ . The sum of 790 divided by the number of normal readings (6) is equal to the mean 131.6 mg/dl.

In the Jane Doe example, the below-normal range mean equals 61.5 mg/dl  
calculated as follows:

10  $\Sigma(55, 68)=123$ . The sum of 123 divided by the number of readings above the normal (2) is equal to the mean 61.5 mg/dl.

In the Jane Doe example, the above-normal range mean equals 280.9 mg/dl  
calculated as follows:

$\Sigma(180, 201, 220, 238, 245, 260, 263, 265, 278, 320, 333, 355, 365, 410)=3933$ .  
15 The sum of 3933 divided by the number of readings above the normal (14) is equal to the mean 280.9 mg/dl.

There are no readings below 40 mg/dl in the Jane Doe example.

There is one reading above 400 mg/dl in the Jane Doe example.

Once the calculations are made, the resultant values are compared to the  
20 pattern label set criteria in a stepwise manner. The first pattern label criteria of the

default set 200 that completely “fits” the patient’s data is selected as the best pattern label. The results of the calculations on Jane Doe’s raw data that are necessary for the pattern label selection process are shown below and in Figure 8:

- Count of Readings during Analysis Period=22
- 5      • % of readings below normal = 9.9%
- % of readings above normal = 63.6%
- Mean of Below Normal Readings = 61.5 mg/dl
- Mean of Above Normal Readings = 280.9 mg/dl

The best fitting pattern label for Jane Doe for the Before Dinner time category  
10 is “Frequent Significant Hyperglycemia,” determined as follows. First, the calculation results are compared to the criteria for “Excellent Control.” The first requirement of a minimum of 10 readings is met. However, Jane Doe does not meet the Below Normal percentage criteria because the Below Normal percentage of 9.9% is greater than the required 0%. Therefore, this pattern label is excluded and the  
15 process proceeds to the next Optimal Control.

Jane Doe meets the minimum readings requirement of 14 for “Optimal Control”, but does not meet the Above Normal percentage criteria because 63.6% (Jane Doe) is greater than 15%(criteria). Therefore, “Optimal Control” is not selected. The process continues until a complete match is found.

20      As the analysis procedure continues, all of the low blood glucose patterns are rejected.

Based on the percentage of readings above normal, frequent hyperglycemia is apparent. The choice between “Frequent Significant Hyperglycemia” and “Frequent Hyperglycemia” is made using the Above Normal mean. Jane Doe’s Above Normal Mean (280.9 mg/dl) is greater than the cut-point (270 mg/dl) thereby distinguishing

5 her readings as elevated enough to be called “significant”. Therefore, “Frequent Significant Hyperglycemia” is selected as the best pattern label to describe Jane Doe’s before dinner glycemic control.

After the pattern label is selected, the data is filtered through the severe reading analysis.

10 As shown, one of Jane Doe’s readings is above 400 mg/dl. The severe reading check would therefore append the suffix “with isolated severe hyperglycemia” to the pattern label 510 for the Before Dinner category.

## Claims

1. A method for the assessment of glycemic control of a human patient using blood glucose readings comprising the steps of:

(1) obtaining a plurality of blood glucose readings taken within a predetermined time category and time period;

(2) performing first calculations on said readings based on a predetermined normal range of glycemia; and

(3) selecting a pattern label having predetermined criteria by comparing the results of said first calculations to the predetermined pattern label criteria to assess the glycemic control of a human patient.

2. The method of Claim 1 further comprising the steps of:

performing second calculations on said readings based on predetermined thresholds for severe hyperglycemia and severe hypoglycemia; and

if the results of said second calculations meet a severity criteria, selecting and appending a severity suffix having predetermined severity criteria to said pattern label by comparing the results of said second calculations to the severity criteria.

3. The method of Claim 2 further comprising the steps of:

performing third calculations on said readings based on a predetermined normal range of glycemia; and

if the results of said third calculations meet a minor comment criteria, selecting and appending a minor comment having predetermined minor comment criteria to said pattern label by comparing the results of said third calculations to said comment criteria.

4. The method of Claim 1 further comprising the step of outputting said pattern label for said time category as at least part of a glycemic control report.

5. The method of Claim 3 further comprising the step of outputting said pattern label for said time category, including any appended severity suffixes and minor comments, as part or all of a glycemic control report.

6. The method of Claim 1 further comprising the step of repeating method steps (1), (2) and (3) for time categories or time periods other than the predetermined time category and time period.

7. The method of Claim 6 further comprising the step of outputting a pattern label for each time category as part or all of a glycemic control report.

8. The method of Claim 5 further comprising the step of repeating the method steps for time categories or time periods other than the predetermined time category and time period.

9. The method for analyzing blood glucose readings of Claim 1 wherein said pattern label is chosen from a pattern label set comprising at least the following labels and criteria:

Pattern Labels	Default Criteria				
	Minimum No. of Readings	Below Normal %	Above Normal %	Below Normal Mean Cutpoint	Above Normal Mean Cutpoint
<b>Normoglycemia</b>					
1. Excellent Control	10	0	0	NA	NA
2. Optimal Control	14	$\leq 10$	$\leq 15$	NA	NA
3. Satisfactory Control	14	$< 20$	$\leq 15$	NA	NA
<b>Low</b>					
4. Clinically Significant Hypoglycemia	14	$\geq 20$ - $< 40$	$\leq 15$	$\leq 0.8x$ (lower bound of normoglycemia)	NA
5. Hypoglycemia (Not Clinically Significant)	14	$\geq 20$ - $< 40$	$\leq 15$	$> 0.8x$ (lower bound of normoglycemia)	NA
6. Frequent Clinically Significant Hypoglycemia	14	$\geq 40$	$\leq 15$	$\leq 0.8x$ (lower bound of normoglycemia)	NA
7. Frequent Hypoglycemia	14	$\geq 40$	$\leq 15$	$> 0.8x$ (lower bound of normoglycemia)	NA
<b>High</b>					
8. Significant Hyperglycemia	14	$\leq 10$	$\geq 15$ - $< 40$	NA	$\geq 1.8x$ (upper bound of normoglycemia)
9. Hyperglycemia	14	$\leq 10$	$\geq 15$ - $< 40$	NA	$< 1.8x$ (upper bound of normoglycemia)
10. Frequent Significant Hyperglycemia	14	$\leq 10$	$\geq 40$	NA	$\geq 1.8x$ (upper bound of normoglycemia)
11. Frequent Hyperglycemia	14	$\leq 10$	$\geq 40$	NA	$< 1.8x$ (upper bound of normoglycemia)
<b>Fluctuant</b>					
12. Widely Fluctuant	14	$\geq 20$	$\geq 30$	NA	NA
13. Fluctuant	14	$\geq 10$	$\geq 10$	NA	NA
<b>Other</b>					
14. Insufficient Data	$< 14$	$\geq 0$	$\geq 0$	NA	NA
15. No Available Data	0	NA	NA	NA	NA

10. The method of Claim 2 wherein said severity suffix is selected from the suffix set comprising the following suffixes and criteria:

Severity Suffix	Severity Suffix Criteria	
	# of readings below low threshold	# of readings above high threshold
With isolated severe hypoglycemia	1 - 3	0
With severe hypoglycemia	>3	0
With isolated severe hyperglycemia	0	1 - 3
With severe hyperglycemia	0	>3
With isolated severe hypoglycemia and isolated severe hypoglycemia	1 - 3	1 - 3
With severe hyperglycemia and severe hypoglycemia	>3	>3

11. The method of Claim 3 wherein said minor comment is selected from the comment set comprising the following comments and criteria:

Pattern Label	Minor Comment	Criteria
Normoglycemia		
Excellent Control	None	NA
Optimal Control	With notable hypoglycemia	Below normal mean <0.8x (lower bound of normal range)
	With several readings at the low end of normal	Within normal mean <1.2x (lower bound of normal range)
	With notable hyperglycemia	Above normal mean >1.8x (upper bound of normal range)
Satisfactory Control	With notable hypoglycemia	Below normal mean <0.8x (lower bound of normal range)
	With several readings at the low end of normal	Within normal mean <1.2x (lower bound of normal range)
	With notable hyperglycemia	Above normal mean >1.8x (upper bound of normal range)
Low		



Clinically Significant Hypoglycemia	With notable hyperglycemia	Above normal mean >1.8x (upper bound of normal range)
Hypoglycemia (Not Clinically Significant)	With notable hyperglycemia	Above normal mean >1.8x (upper bound of normal range)
Frequent Clinically Significant Hypoglycemia	With notable hyperglycemia	Above normal mean >1.8x (upper bound of normal range)
Frequent Hypoglycemia	With notable hyperglycemia	Above normal mean >1.8x (upper bound of normal range)
<b>High</b>		
Significant Hyperglycemia	With notable hypoglycemia	Below normal mean <0.8x (lower bound of normal range)
	With several readings at the low end of normal	Within normal mean <1.2x (lower bound of normal range)
Hyperglycemia	With notable hypoglycemia	Below normal mean <0.8x (lower bound of normal range)
	With several readings at the low end of normal	Within normal mean <1.2x (lower bound of normal range)
Frequent Significant Hyperglycemia	With notable hypoglycemia	Below normal mean <0.8x (lower bound of normal range)
	With several readings at the low end of normal	Within normal mean <1.2x (lower bound of normal range)
Frequent Hyperglycemia	With notable hypoglycemia	Below normal mean <0.8x (lower bound of normal range)
	With several readings at the low end of normal	Within normal mean <1.2x (lower bound of normal range)
<b>Fluctuant</b>		
Widely Fluctuant	With a range from (lowest mg/dl to highest mg/dl)	Added to all
Fluctuant	With a range from lowest (mg/dl to highest mg/dl)	Added to all
<b>Other</b>		
Insufficient Data	None	NA
No Available Data	None	NA

12. The method of Claim 1 wherein said first calculations comprise computing:

The number of readings in the time category within the time period;

The percentage of readings within the normal range of glycemia;

The percentage of readings above the normal range of glycemia;

The percentage of readings below the normal range of glycemia;

The mean of readings within the normal range of glycemia;

The mean of readings above the normal range of glycemia; and

The mean of readings below the normal range of glycemia.

13. The method of Claim 2 wherein said second calculations comprise counting the number of readings above a predetermined high glycemia threshold and the number below a low glycemia threshold.

14. The method of Claim 3 wherein said third calculations comprise calculating the mean of readings above normal glycemia, the mean of readings below normal glycemia, and the mean of readings within a normal range of glycemia.

15. The method of analyzing blood glucose readings of Claim 1 wherein the step of performing calculations on said readings further comprises the steps of:

Counting the number of readings in the time category within the time period;

Calculating the quantity of readings above, below and within predetermined normal range of glycemia;

Calculating the mean of readings above, the mean below and the mean within a predetermined normal range of glycemia; and

Calculating the quantity of readings outside predetermined severe glycemia thresholds.

16. A glycemic control report comprising a pattern label for a predetermined time category within a predetermined time period.
17. A glycemic control report comprising a pattern label and severity suffix for a predetermined time category within a predetermined time period.
18. A glycemic control report comprising a pattern label and a minor comment for a predetermined time category within a predetermined time period.
19. A computer system for the assessment of glycemic control using the method of Claim 1.
20. A computer system for the assessment of glycemic control using the method of Claim 2.
21. A computer system for the assessment of glycemic control using the method of Claim 3.
22. A computer system for the assessment of glycemic control using the method of Claim 4.
23. A computer system for the assessment of glycemic control using the method of Claim 5.
24. A computer system for the assessment of glycemic control using the method of Claim 6.

25. A computer system for the assessment of glycemic control using the method of Claim 7.

26. A computer system for the assessment of glycemic control using the method of Claim 8.

27. A computer for creating a glycemic control report of Claim 16.

28. A computer for creating a glycemic control report of Claim 17.

29. A computer for creating a glycemic control report of Claim 18.

30. A computer-readable medium containing instructions to cause a computer system to perform the method of Claim 1.

31. A computer-readable medium containing instructions to cause a computer system to perform the method of Claim 2.

32. A computer-readable medium containing instructions to cause a computer system to perform the method of Claim 3.

33. A computer-readable medium containing instructions to cause a computer system to perform the method of Claim 4.

34. A computer-readable medium containing instructions to cause a computer system to perform the method of Claim 5.

35. A computer-readable medium containing instructions to cause a computer system to perform the method of Claim 6.

36. A computer-readable medium containing instructions to cause a computer system to perform the method of Claim 7.

37. A computer-readable medium containing instructions to cause a computer system to perform the method of Claim 8.

1/8




FIGURE 1

2/8

200↓

Pattern Labels 201	Default Criteria 202				
	Minimum No. of Readings	Below Normal %	Above Normal %	Below Normal Mean Culpoint	Above Normal Mean Culpoint
<b>Normoglycemia</b>					
1. Excellent Control	10	0	0	NA	NA
2. Optimal Control	14	≤10	≤15	NA	NA
3. Satisfactory Control	14	<20	≤15	NA	NA
<b>Hypoglycemia</b>					
4. Clinically Significant Hypoglycemia	14	≥20- <40	≤15	≤0.8x (lower bound of normoglycemia)	NA
5. Hypoglycemia (Not Clinically Significant)	14	≥20- <40	≤15	>0.8x (lower bound of normoglycemia)	NA
6. Frequent Clinically Significant Hypoglycemia	14	≥40	≤15	≤0.8x (lower bound of normoglycemia)	NA
7. Frequent Hypoglycemia	14	≥40	≤15	>0.8x (lower bound of normoglycemia)	NA
<b>Hyperglycemia</b>					
8. Significant Hyperglycemia	14	≤10	≥15- <40	NA	≥1.8x (upper bound of normoglycemia)
9. Hyperglycemia	14	≤10	≥15- <40	NA	<1.8x (upper bound of normoglycemia)
10. Frequent Significant Hyperglycemia	14	≤10	≥40	NA	≥1.8x (upper bound of normoglycemia)
11. Frequent Hyperglycemia	14	≤10	≥40	NA	<1.8x (upper bound of normoglycemia)
<b>Fluctuation</b>					
12. Widely Fluctuant	14	≥20	≥30	NA	NA
13. Fluctuant	14	≥10	≥10	NA	NA
<b>Other</b>					
14. Insufficient Data	<14	≥0	≥0	NA	NA
15. No Available Data	0	NA	NA	NA	NA

FIGURE 2

Severity Suffix Criteria <u>302</u>		
Severity Suffix <u>300</u>	# of readings below low threshold	# of readings above high threshold
With isolated severe hypoglycemia	1 - 3	0
With severe hypoglycemia	>3	0
With isolated severe hyperglycemia	0	1 - 3
With severe hyperglycemia	0	>3
With isolated severe hyperglycemia and isolated severe hypoglycemia	1 - 3	1 - 3
With severe hyperglycemia and severe hypoglycemia	>3	>3

FIGURE 3



Pattern Label	Minor comment 400	Criteria 402
<b>Normoglycemia</b>		
Excellent Control	None	NA
Optimal Control	With notable hypoglycemia	Below normal mean <0.8x (lower bound of normal range)
	With several readings at the low end of normal	Within normal mean <1.2x (lower bound of normal range)
	With notable hyperglycemia	Above normal mean >1.8x (upper bound of normal range)
Satisfactory Control	With notable hypoglycemia	Below normal mean <0.8 (lower bound of normal range)
	With several readings at the low end of normal	Within normal mean <1.2 (lower bound of normal range)
	With notable hyperglycemia	Above normal mean >1.8x (upper bound of normal range)
<b>Low</b>		
Clinically Significant Hypoglycemia	With notable hyperglycemia	Above normal mean >1.8x (upper bound of normal range)
Hypoglycemia (Not Clinically Significant)	With notable hyperglycemia	Above normal mean >1.8x (upper bound of normal range)
	With notable hyperglycemia	Above normal mean >1.8x (upper bound of normal range)
Frequent Clinically Significant Hypoglycemia	With notable hyperglycemia	Above normal mean >1.8x (upper bound of normal range)
Frequent Hypoglycemia	With notable hyperglycemia	Above normal mean >1.8x (upper bound of normal range)
<b>High</b>		
Significant Hyperglycemia	With notable hypoglycemia	Below normal mean <0.8x (lower bound of normal range)
	With several readings at the low end of normal	Within normal mean <1.2x (lower bound of normal range)
Hyperglycemia	With notable hypoglycemia	Below normal mean <0.8x (lower bound of normal range)
	With several readings at the low end of normal	Within normal mean <1.2x (lower bound of normal range)
Frequent Significant Hyperglycemia	With notable hypoglycemia	Below normal mean <0.8x (lower bound of normal range)
	With several readings at the low end of normal	Within normal mean <1.2x (lower bound of normal range)
Frequent Hyperglycemia	With notable hypoglycemia	Below normal mean <0.8x (lower bound of normal range)
	With several readings at the low end of normal	Within normal mean <1.2x (lower bound of normal range)
<b>Fluctuant</b>		
Widely Fluctuant	With a range from (lowest mg/dl to highest mg/dl)	Added to all
Fluctuant	With a range from (lowest mg/dl to highest mg/dl)	Added to all
<b>Other</b>		
Insufficient Data	None	NA
No Available Data	None	NA

FIGURE 4

5/8




FIGURE 5

6/8

MEMBER ID: 010010100101 | NAME: JANE DOE | HOME PHONE: 314.527.8888 | OFFICE PHONE: 314.535.1871 | CARE PROVIDER: DR. JONATHAN BORTZ, MD

**Diabetes Dashboard™**

Report Date: 1/30/2001  
 Analysis Period: Jan 1, 2001 - Jan 30, 2001  
 Unit of Measure: mg/dl  
 Target Range: 71-150  
 Normal Range: 71-125 (BG), 71-150 (BL, RD, BED)  
 Data Source: 100% Direct Meter Upload


AGE 58 HEIGHT 5'11" LDL 146 BP 126/58  
 GENDER F WEIGHT 180 HDL 29  
 TYPE 1 BMI 26 TOTAL 245

**Complications and Risk Factors**

☒ Smoker ☒ Retinopathy  
☒ Hypertension ☒ Nephropathy  
☒ Coronary Heart Disease ☒ Neuropathy

**Associated Medications**

ACE Inhibitor ☒ Statin ☒ Other  
 Monopril ☒ Pravastatin ☒ Atenolol ☒

**Disease Management Plan**

602

**Assessment of Glycemic Control**




Summary assessment of glycemic control from 1/1 to 1/30:

Before Breakfast: Hypoglycemia, with isolated severe hypoglycemia.

Before Lunch: Insufficient data for complete analysis.

Before Dinner: Frequent Significant Hyperglycemia, with isolated severe hypoglycemia.

Before Bedtime: Insufficient data for complete analysis, with severe hypoglycemia.

**For Office Use****Pre-Meal Overview: Jan 1 - Jan 30****Overall Control: Dec 30 - Jan 30****30-Day Summary / Pre-Meal: Jan 1 - Jan 30**

● Before Breakfast ☒ Medication Change  
 ■ Before Lunch ☒ Comment / Explanation  
 ✕ Before Dinner ☒ Saturday  
 ◆ Bedtime

Medication Change ☒  
 1/22 Decrease Regular Insulin from 5 units to 3 units at Before Dinner.

**Current Diabetes Medications**

Insulin	Oral
BB 50 N 20 R	Gliclazide 2.5/500
BL	
RD 3 R	
BED	

FIGURE 6

7/8

MEMBER ID: 0100100101 | NAME: JANE, DOE | HOME PHONE: 314.567.8000 | OFFICE PHONE: 314.535.1871 | CARE PROVIDER: DR. JONATHAN BORTZ, MD

**Diabetes Dashboard™** Page

## 30-Day Overview Comments (Comments are linked to 30-Day Overview on page 1)

#	Date	Comment
1	1/10	BD - Forgot to take insulin.
2	1/24	BED - Don't know why sugars were low.
#		
#		

## Raw Data

	12:00 AM	2:00 AM	4:00 AM	6:00 AM	8:00 AM	10:00 AM	12:00 PM	2:00 PM	4:00 PM	6:00 PM	8:00 PM	10:00 PM	12:00 AM	2:00 AM	4:00 AM	6:00 AM	8:00 AM	10:00 AM	12:00 PM	2:00 PM	4:00 PM	6:00 PM	8:00 PM	10:00 PM	12:00 AM
1/1	140	55	82	84	121	104	87	103	108	100	106	104	140	55	82	84	121	104	87	103	108	100	106	104	140
1/2	140	55	82	84	121	104	87	103	108	100	106	104	140	55	82	84	121	104	87	103	108	100	106	104	140
1/3	140	55	82	84	121	104	87	103	108	100	106	104	140	55	82	84	121	104	87	103	108	100	106	104	140
1/4	140	55	82	84	121	104	87	103	108	100	106	104	140	55	82	84	121	104	87	103	108	100	106	104	140
1/5	140	55	82	84	121	104	87	103	108	100	106	104	140	55	82	84	121	104	87	103	108	100	106	104	140
1/6	140	55	82	84	121	104	87	103	108	100	106	104	140	55	82	84	121	104	87	103	108	100	106	104	140
1/7	140	55	82	84	121	104	87	103	108	100	106	104	140	55	82	84	121	104	87	103	108	100	106	104	140
1/8	140	55	82	84	121	104	87	103	108	100	106	104	140	55	82	84	121	104	87	103	108	100	106	104	140
1/9	140	55	82	84	121	104	87	103	108	100	106	104	140	55	82	84	121	104	87	103	108	100	106	104	140
1/10	140	55	82	84	121	104	87	103	108	100	106	104	140	55	82	84	121	104	87	103	108	100	106	104	140
1/11	140	55	82	84	121	104	87	103	108	100	106	104	140	55	82	84	121	104	87	103	108	100	106	104	140
1/12	140	55	82	84	121	104	87	103	108	100	106	104	140	55	82	84	121	104	87	103	108	100	106	104	140
1/13	140	55	82	84	121	104	87	103	108	100	106	104	140	55	82	84	121	104	87	103	108	100	106	104	140
1/14	140	55	82	84	121	104	87	103	108	100	106	104	140	55	82	84	121	104	87	103	108	100	106	104	140
1/15	140	55	82	84	121	104	87	103	108	100	106	104	140	55	82	84	121	104	87	103	108	100	106	104	140
1/16	140	55	82	84	121	104	87	103	108	100	106	104	140	55	82	84	121	104	87	103	108	100	106	104	140
1/17	140	55	82	84	121	104	87	103	108	100	106	104	140	55	82	84	121	104	87	103	108	100	106	104	140
1/18	140	55	82	84	121	104	87	103	108	100	106	104	140	55	82	84	121	104	87	103	108	100	106	104	140
1/19	140	55	82	84	121	104	87	103	108	100	106	104	140	55	82	84	121	104	87	103	108	100	106	104	140
1/20	140	55	82	84	121	104	87	103	108	100	106	104	140	55	82	84	121	104	87	103	108	100	106	104	140
1/21	140	55	82	84	121	104	87	103	108	100	106	104	140	55	82	84	121	104	87	103	108	100	106	104	140
1/22	140	55	82	84	121	104	87	103	108	100	106	104	140	55	82	84	121	104	87	103	108	100	106	104	140
1/23	140	55	82	84	121	104	87	103	108	100	106	104	140	55	82	84	121	104	87	103	108	100	106	104	140
1/24	140	55	82	84	121	104	87	103	108	100	106	104	140	55	82	84	121	104	87	103	108	100	106	104	140
1/25	140	55	82	84	121	104	87	103	108	100	106	104	140	55	82	84	121	104	87	103	108	100	106	104	140
1/26	140	55	82	84	121	104	87	103	108	100	106	104	140	55	82	84	121	104	87	103	108	100	106	104	140
1/27	140	55	82	84	121	104	87	103	108	100	106	104	140	55	82	84	121	104	87	103	108	100	106	104	140
1/28	140	55	82	84	121	104	87	103	108	100	106	104	140	55	82	84	121	104	87	103	108	100	106	104	140
1/29	140	55	82	84	121	104	87	103	108	100	106	104	140	55	82	84	121	104	87	103	108	100	106	104	140
1/30	140	55	82	84	121	104	87	103	108	100	106	104	140	55	82	84	121	104	87	103	108	100	106	104	140

## Legend

Time Categories	
BB - Before Breakfast	AB - After Breakfast
BL - Before Lunch	AL - After Lunch
BD - Before Dinner	AD - After Dinner
BED - Bed Time	NGT - Night

FIGURE 7

8/8

Pattern Label Analysis Calculations For Each Time Category	Jane Doe Example (Before Dinner)
Number of readings in time category	22
% of readings within Normal Glycemic Range	27.3%
% of readings below Normal Glycemic Range	9.9%
% of readings above Normal Glycemic Range	63.6%
Mean of readings within the Normal Glycemic Range (mg/dl)	131.6
Mean of readings below the Normal Glycemic Range (mg/dl)	61.5
Mean of readings above the Normal Glycemic Range (mg/dl)	280.9
Severity Suffix Analysis Calculations for Each Time Category	
Number of readings below low threshold	0
Number of readings above high threshold	1

FIGURE 8

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
7 August 2003 (07.08.2003)

PCT

(10) International Publication Number  
**WO 2003/065033 A3**

(51) International Patent Classification<sup>7</sup>: **G06F 19/00**,  
17/00

(21) International Application Number:  
PCT/US2003/002429

(22) International Filing Date: 27 January 2003 (27.01.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
10/059,084 28 January 2002 (28.01.2002) US

(71) Applicant: **CONTROL DIABETES, INC.** [US/US];  
6520 Clayton Road, St. Louis, MO 63117 (US).

(72) Inventors: **BORTZ, Jonathan, David**; 8117 Stanford Avenue,  
St. Louis, MO 63130 (US); **ARMBRIST, Eric, Stephen**; 525 Clara Avenue #202, St. Louis, MO 63112  
(US).


(74) Agent: **DIGIROLAMO, Samuel**; Blackwell Sanders  
Pepper Martin LLP, 720 Olive Street, Suite 2400, St. Louis,  
MO 63101 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,  
SG, SK, SI, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC,  
VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, SE, SI,  
SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: METHODS AND SYSTEMS FOR ASSESSING GLYCEMIC CONTROL USING PREDETERMINED PATTERN LABEL ANALYSIS OF BLOOD GLUCOSE READINGS



(57) Abstract: Methods and systems for analyzing blood glucose readings comprising the steps of obtaining a plurality of blood glucose readings taken within a predetermined time category and time period, performing first calculations on said readings based on a predetermined normal range of glycemia in a first analysis and selecting and applying a pattern label having predetermined criteria to the plurality of blood glucose readings by comparing the results of the first calculations to the pattern label criteria. The invention may also include the steps of performing second calculations on said readings based on predetermined thresholds for severe hyperglycemia and severe hypoglycemia and selecting and appending a severity suffix having predetermined severity criteria to said pattern label by comparing the results of the second calculations to the severity criteria as well as performing third calculations on said readings based on a predetermined normal range of glycemia and selecting and appending a minor comment having minor comment criteria to said pattern label by comparing the results of the third calculations to the comment criteria.



**Published:**

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**(88) Date of publication of the international search report:**

5 February 2004

## INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/US 03/02429

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 G06F19/00 G06F17/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G06F G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, MEDLINE, BIOSIS, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>KOVATCHEV B P ET AL: "Assessment of risk for severe hypoglycemia among adults with IDDM: validation of the low blood glucose index."</p> <p>DIABETES CARE. UNITED STATES NOV 1998, vol. 21, no. 11, November 1998 (1998-11), pages 1870-1875, XP002256623</p> <p>ISSN: 0149-5992</p> <p>the whole document</p> <p>---</p> <p>-/--</p>	1-15, 30-37

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date, but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

Date of the actual completion of the international search

6 October 2003

Date of mailing of the international search report

22/10/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5618 Patentlaan 2  
NL - 2200 HV Rijswijk  
Tel: (+31-70) 340-2040, Tx: 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Thumb, W



## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 03/02429

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	KOVATCHEV BORIS P ET AL: "Episodes of severe hypoglycemia in type 1 diabetes are preceded and followed within 48 hours by measurable disturbances in blood glucose" JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 85, no. 11, November 2000 (2000-11), pages 4287-4292, XP002256624 ISSN: 0021-972X the whole document	1-15, 30-37
A	WO 01 72208 A (KOVATCHEV BORIS P ; UNIV VIRGINIA (US); COX DANIEL J (US)) 4 October 2001 (2001-10-04) the whole document	1-15, 30-37
A	EP 0 483 595 A (MILES INC) 6 May 1992 (1992-05-06) the whole document	1-15, 30-37

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 03/02429**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-8, 12-37  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.: 1-8, 12-15, 19-29:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box I.1

Although claim 1-15 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged outcome of the method of claims 1-15. The expression "obtaining a plurality of blood glucose readings" is so broad that it also encompasses methods including taking a sample of blood from a subject.

---

## Continuation of Box I.1

Claims Nos.: 1-8, 12-37

Rule 39.1(iv) PCT - Diagnostic method practised on the human or animal body (Claims 1-15)

Rule 39.1(v) PCT - Presentation of information Rule 39.1(iv) (Claims 16-18)

---

## Continuation of Box I.2

Claims Nos.: 1-8, 12-15, 19-29

Present claims 1-8 and 12-15 relate to a method for the assessment of glycemic control, comprising the steps of "selecting a pattern label", selecting a "severity suffix" and selecting "minor comment criteria" from calculations based on blood glucose readings.

The terms "pattern label", "severity suffix" and "minor comment criteria" do not have a well defined meaning in the art and appear to be arbitrarily chosen. Due to the complete lack of technical features it is impossible for a person skilled in the art to determine the scope of the method for which protection is sought. In addition, no technical features of the calculation steps of claims 1-3 are defined, thus rendering execution of the method of at least claims 1-3 impossible. This lack of clarity within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. Consequently, the search has been carried out for those parts of the application which do appear to be clear, namely a method including all of the calculation steps of claims 13-15 and the criteria set forth in claims 9-11.

A similar argumentation also applies to the subject-matter of claims 30-37, referring to a computer-readable medium containing instructions to cause a computer system to perform the method of claims 1-8. Again, the lack of technical features results in a lack of clarity (Article 6 PCT) to such an extent as to render a meaningful search impossible.

Claims 19-29 refer to computer systems for the assessment of glycemic control using the methods of the present application. Again no technical features whatsoever are defined. Claims 19-29 are therefore so unclear within the meaning of Article 6 PCT that no meaningful search can be performed.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/02429

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0172208	A	04-10-2001	AU	5104601 A	08-10-2001
			CA	2404262 A1	04-10-2001
			CN	1422136 T	04-06-2003
			EP	1267708 A2	02-01-2003
			WO	0172208 A2	04-10-2001
EP 0483595	A	06-05-1992	US	5251126 A	05-10-1993
			AT	210321 T	15-12-2001
			AU	637711 B2	03-06-1993
			AU	8020591 A	07-05-1992
			CA	2051914 A1	30-04-1992
			DE	69132847 D1	17-01-2002
			DE	69132847 T2	11-04-2002
			DK	483595 T3	08-04-2002
			EP	0483595 A2	06-05-1992
			ES	2167309 T3	16-05-2002
			JP	3241409 B2	25-12-2001
			JP	4348747 A	03-12-1992